Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Oncolytics Biotech Inc (ONCY)

Oncolytics Biotech Inc (ONCY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 103,891
  • Shares Outstanding, K 59,029
  • Annual Sales, $ 0 K
  • Annual Income, $ -20,990 K
  • 60-Month Beta 2.06
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.14
Trade ONCY with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.05
  • Number of Estimates 1
  • High Estimate -0.05
  • Low Estimate -0.05
  • Prior Year -0.11
  • Growth Rate Est. (year over year) +54.55%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2300 +43.09%
on 11/03/22
1.9900 -11.56%
on 11/10/22
+0.5100 (+40.80%)
since 10/28/22
3-Month
1.1500 +53.04%
on 10/14/22
1.9900 -11.56%
on 11/10/22
+0.3500 (+24.82%)
since 08/30/22
52-Week
0.8021 +119.42%
on 06/14/22
2.0800 -15.38%
on 02/10/22
-0.0500 (-2.76%)
since 11/26/21

Most Recent Stories

More News
Big Developments Set to be Unveiled at This Year's San Antonio Breast Cancer Symposium (SABCS)

/PRNewswire/ -- USA News Group - A new study has revealed that women diagnosed with benign breast disease through screening have an almost double risk of...

ONC.TO : 2.36 (+5.83%)
ONCY : 1.7600 (+7.32%)
LLY : 371.08 (+1.96%)
NEO : 11.21 (+10.77%)
ZYME : 7.72 (+0.13%)
GTHX : 5.96 (+5.67%)
Big Developments Set to be Unveiled at This Year’s San Antonio Breast Cancer Symposium (SABCS)

EQNX::TICKER_START (NASDAQ:ONCY),(NYSE:LLY),(NASDAQ:NEO),(NYSE:ZYME),(NASDAQ:GTHX) EQNX::TICKER_END

ONCY : 1.7600 (+7.32%)
ONC.TO : 2.36 (+5.83%)
LLY : 371.08 (+1.96%)
NEO : 11.21 (+10.77%)
ZYME : 7.72 (+0.13%)
GTHX : 5.96 (+5.67%)
Biotech Sector to Unveil New Data and Developments at 2022 SABCS in San Antonio

USA News Group – A new study has revealed that women diagnosed with benign breast disease through screening have an almost double risk of acquiring breast cancer. The findings come ahead of this year’s...

ONCY : 1.7600 (+7.32%)
ONC.TO : 2.36 (+5.83%)
LLY : 371.08 (+1.96%)
NEO : 11.21 (+10.77%)
ZYME : 7.72 (+0.13%)
GTHX : 5.96 (+5.67%)
Is Olink Holding (OLK) Outperforming Other Medical Stocks This Year?

Here is how Olink Holding AB publ Sponsored ADR (OLK) and Oncolytics Biotech Inc. (ONCY) have performed compared to their sector so far this year.

OLK : 23.83 (+3.56%)
ONCY : 1.7600 (+7.32%)
Oncolytics Biotech® Announces Presentations at the Upcoming San Antonio Breast Cancer Symposium

/PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the publication of two abstracts for poster presentations at the upcoming...

ONC.TO : 2.36 (+5.83%)
ONCY : 1.7600 (+7.32%)
Oncolytics Biotech® Announces Presentations at the Upcoming San Antonio Breast Cancer Symposium

/CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the publication of two abstracts for poster presentations at the upcoming San...

ONCY : 1.7600 (+7.32%)
ONC.TO : 2.36 (+5.83%)
Oncolytics Biotech Inc. (ONCY) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

After losing some value lately, a hammer chart pattern has been formed for Oncolytics Biotech Inc. (ONCY), indicating that the stock has found support. This, combined with an upward trend in earnings estimate...

ONCY : 1.7600 (+7.32%)
Biotech Sector Witnessing Growing Revenue Potential in Ongoing Battle Against Pancreatic Cancer

USA News Group – Roughly five years after selling its flagship cancer asset Onivyde from to French biotech giant Ipsen S.A. for approximately $1 billion, Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK)...

ONCY : 1.7600 (+7.32%)
ONC.TO : 2.36 (+5.83%)
SGEN : 121.39 (+3.43%)
MRTX : 91.38 (+2.95%)
AMGN : 286.40 (+1.56%)
MACK : 11.91 (+0.76%)
Biotech Sector Witnessing Growing Revenue Potential in Ongoing Battle Against Pancreatic Cancer

FN Media Group Presents USA News Group News Commentary   Vancouver, BC –November 15, 2022 – USA News Group  –  Roughly five years after selling its flagship cancer asset Onivyde from to French...

ONCY : 1.7600 (+7.32%)
ONC.TO : 2.36 (+5.83%)
SGEN : 121.39 (+3.43%)
MRTX : 91.38 (+2.95%)
AMGN : 286.40 (+1.56%)
MACK : 11.91 (+0.76%)
Biotech Sector Gaining Wins Against Pancreatic Cancer with Early Detection and New Therapies

/PRNewswire/ -- USA News Group - English actor, comedian and Monty Python alumnus Eric Idle credits early detection for his victory over pancreatic cancer,...

ONC.TO : 2.36 (+5.83%)
ONCY : 1.7600 (+7.32%)
RHHBY : 40.9200 (+0.64%)
LLY : 371.08 (+1.96%)
BMY : 80.28 (+1.58%)
BNTX : 167.02 (+2.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

See More Share

Business Summary

Oncolytics Biotech, Inc. focuses on the discovery and development of pharmaceutical products for the treatment of a wide variety of human and companion pet cancers. The Company was formed to explore the oncolytic capability of the reovirus, a virus that preferentially replicates in cells with an activated...

See More

Key Turning Points

3rd Resistance Point 1.9867
2nd Resistance Point 1.8733
1st Resistance Point 1.8167
Last Price 1.7600
1st Support Level 1.6467
2nd Support Level 1.5333
3rd Support Level 1.4767

See More

52-Week High 2.0800
Last Price 1.7600
Fibonacci 61.8% 1.5918
Fibonacci 50% 1.4410
Fibonacci 38.2% 1.2903
52-Week Low 0.8021

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar